Overview
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
Status:
Completed
Completed
Trial end date:
2015-03-01
2015-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with chronic phase or elderly schizophrenia.Phase:
Phase 2/Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Mitsubishi Tanabe Pharma CorporationTreatments:
Risperidone
Criteria
Inclusion Criteria:- Written informed consent obtained from the patient before the initiation of any
study-specific procedures
- Patients diagnosed with schizophrenia according to the diagnostic criteria of the
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision
(DSM-IV-TR) criteria for schizophrenia
- Patients who meet at least one of the following:
- current diagnosis of schizophrenia of chronic phase
- between 65 and 74 years of age
- Patients with normal physical examination, laboratory, vital signs, and/or
electrocardiogram (ECG)
Exclusion Criteria:
- Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform
disorder, other psychotic disorders other than schizophrenia, or bipolar I or II
disorder
The information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.